Incretin Atlas › Trials › Survodutide phase 2 MASH
Survodutide phase 2 MASH
Survodutide · MASH F1–F3
Design
- Molecule(s)
- Survodutide
- Population
- MASH F1–F3
- Official title
- A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
- Sponsor
- Boehringer Ingelheim
- Phase
- Phase 2
- Registry status
- completed · 2021-04 → 2023-11
- Participants
- 295
- Duration
- 48 weeks
- Registry
- NCT04771273
Outcomes in the indication
Survodutide phase 2 MASH Survodutide · MASH F1–F3 · 48 weeks · n = 293 seed
Histological improvement of MASH 83 % vs 18 %
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Survodutide phase 2 MASH. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/survodutide-phase-2-mash/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.